| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
study archive
with methacholine |
Lung, respiratory function, baseline and methacholine-challenged (several doses). | QTL population | f | 7-8wks | 2005 |
|
|
body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). | inbred (15) | both | 6-14wks | 1999 |
|
|
protein activity assessment
with high-fat diet |
Phospholipid transfer protein activity. 4h fast. | inbred (15) | both | 6-14wks | 1999 |
|
|
study archive | Body, organ, fat pad weights, weight gain, litter size. | QTL population | both | 2-10wks | 2009 |
|
|
body weight
with high-fat high-sucrose diet |
Weekly. | DO population | both | 4-26wks | 2018 |
|
|
intake monitoring
with high-fat high-sucrose diet |
Food intake. Weekly. | DO population | both | 4-26wks | 2018 |
|
|
metabolic panel
with high-fat high-sucrose diet |
Glucose, HOMA-IR, HOMA-B. | DO population | both | 4-26wks | 2018 |
|
|
hormone quantification
with high-fat high-sucrose diet |
Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. | DO population | both | 4-26wks | 2018 |
|
|
lipid profile
with high-fat high-sucrose diet |
Triglyceride. | DO population | both | 4-26wks | 2018 |
|
|
glucose tolerance
with high-fat high-sucrose diet |
Area under curve. | DO population | both | 4-26wks | 2018 |
|
|
biomarker quantification
with high-fat high-sucrose diet |
Bile acids in feces. | DO population | both | 4-26wks | 2018 |
|
|
body weight
with high-fat diet |
8-29 wks of age. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
NMR
with high-fat diet |
Body composition. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
intake monitoring
with high-fat diet |
Food intake. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption and respiratory exchange ratio (RER); activity. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
glucose tolerance
with high-fat diet |
Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
hormone quantification
with high-fat diet |
Glucose post oral gavage: 0, 15, 30 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
body temperature
with high-fat diet |
In cold room: 0, 1, 2, 3, 4, 5, 6 h. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
treadmill endurance test
with high-fat diet |
Distance traveled. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
running wheel monitoring
with high-fat diet |
Distance traveled, speed. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
metabolic panel
with high-fat diet |
Enzymes, bile acid, proteins, creatinine, glucose, iron, lactate. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, LDL, free fatty acids, triglyceride. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
cell signaling molecule detection
with high-fat diet |
INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
body weight
with high-fat diet |
inbred w/CC8 | both | 8-21 wks | 2021 | |
|
|
monitoring system
with high-fat diet |
Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
hormone quantification
with high-fat diet |
Insulin levels following glucose post oral gavage: 0, 15, 30 min. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
intake monitoring
with high-fat diet |
Food intake. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
treadmill endurance test
with high-fat diet |
Distance traveled. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
metabolic panel
with high-fat diet |
Enzymes, creatinine, iron, lactate, urea. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, LDL, triglycerides, free fatty acids. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
intake monitoring | Water intake. Daily. | inbred (13) | m | 7-8wks | 2011 |
|
|
bottle choice test | Sodium chloride solution taste threshold. Fluid intake. | inbred (13) | m | 7-8wks | 2011 |
|
|
body weight | Body weight | inbred (13) | m | 7-8wks | 2011 |
|
|
study archive | Open field test. Locomotor activity, anxiety-related behavior. | QTL population | both | 8wks | 2008 |
|
|
study archive | Plasma lipids. Cholesterol, triglycerides. | QTL population | both | 12-14wks | 2013 |
|
|
study archive | Bone morphology and strength, insulin-like growth factor 1. | QTL population | f | 16wks | 2001 |
|
|
body weight | Body weight and growth curve from 4wks to 26wks weighed monthly. | ILSXISS (97) | f | 6wks | 2005 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. | ILSXISS w/par (74) | both | 8-14wks | 2007 |
|
|
body weight | Body weight | both | 8-20wks | 2021 | |
|
|
MRI | Body composition (lean, fat, water). | both | 8-20wks | 2021 | |
|
|
metabolic panel | Plasma enzymes, creatinine, glucose, urea, metabolic health score. | both | 8-20wks | 2021 | |
|
|
lipid profile | Cholesterol, non-esterified fatty acids, triglyceride. | both | 8-20wks | 2021 | |
|
|
biomarker quantification | TMAO, choline, phosphocholine, glycerophosphocholine, betaine, carnitine. | both | 8-20wks | 2021 | |
|
|
hormone quantification | Insulin, glucose:insulin ratio. | both | 8-20wks | 2021 | |
|
|
monitoring system | O2 consumption, CO2 production, RER, heat expenditure, activity. | both | 8-20wks | 2021 | |
|
|
intake monitoring | Food intake; energy intake; protein, carbohydrate, fat intake. | both | 8-20wks | 2021 | |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
plethysmography
with methacholine |
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
ventilator
with methacholine |
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
metabolite quantification | Vitamin D concentration (serum). | inbred (18) | m | 11wks | 2011 |
|
|
intake monitoring
with sucrose |
Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. | inbred (12) | m | 13-17wks | 2006 |
|
|
open field test | Locomotor activity and exploratory behavior. 5 min test in dark. | inbred (10) | both | 8-14wks | 2000 |
|
|
fear conditioning test | Contextual fear, cued fear. | inbred (8) | both | 9-20wks | 2001 |
|
|
monitoring system | Social interaction (study 1 and study 2). | inbred (7) | m | 8-12wks | 2007 |
|
|
open field test | Locomotor activity, exploratory behavior, habituation scores. 15 min test. | inbred (14) | m | 8-12wks | 2009 |
|
|
body weight
with influenza A (H5N1) virus |
Influenza A (H5N1) virus (several doses) vs. baseline. | inbred (23) | f | 6-9wks | 2011 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
study archive | Protein tau hyperphosphorylation. | QTL population | f | 3wks | 2003 |
|
|
body weight
with Theiler's murine encephalomyelitis virus |
Body weight | CC (5) | both | 4wks | 2017 |
|
|
open field test
with Theiler's murine encephalomyelitis virus |
Locomotor activity, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
gait analysis
with Theiler's murine encephalomyelitis virus |
DigiGait analysis and footprint analysis, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
rotarod
with Theiler's murine encephalomyelitis virus |
Latency to fall from accelerating rotarod, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
study archive | Body, organ weights, litter size, abdominal fat, lipids, insulin, leptin. | QTL population | both | 3-6wks | 2009 |
|
|
elevated plus maze | Locomotor, exploratory, and anxiety-related behavior. | inbred (14) | both | 10wks | 2004 |
|
|
elevated zero maze | Locomotor, exploratory, and anxiety-related behavior. | inbred (14) | both | 10wks | 2004 |
|
|
light-dark box | Anxiety, avoidance behavior. | inbred (14) | both | 10wks | 2004 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. | inbred (14) | both | 10wks | 2004 |
|
|
Barnes circular maze | Spatial learning and memory. | inbred (14) | both | 10-18wks | 2004 |
|
|
Morris water maze | Spatial learning and memory. | inbred (14) | both | 10-18wks | 2004 |
|
|
rotarod | Latency to fall from accelerating rotarod. 7 day trials. | inbred (14) | both | 10-18wks | 2004 |
|
|
visual water box | Spatial learning and memory. | inbred (14) | both | 10-18wks | 2004 |
|
|
olfactory discrimination task | Olfactory-related learning and memory. | inbred (14) | both | 10-18wks | 2004 |
|
|
complete blood count | Hematology. | inbred (10) | both | 8wks | 2013 |
|
|
ion transport assessment | Hematology red cell ion content, ion transport. | inbred (10) | both | 8wks | 2013 |
|
|
monitoring system
with morphine |
Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). | inbred w/CC8 (8) | both | 8-24wks | 2020 |
|
|
study archive | Femur and vertebra morphology and strength. Monthly body weight 3 - 13 months. | QTL population | f | 14-56wks | 2012 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
|
metabolic panel | Glucose (plasma). 4h fast. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
complete blood count | Hematology. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
body weight | Body weight | CC diallel w/par (62) | both | 8-16wks | 2012 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
complete blood count | Hematology. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 10 min test. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
light-dark box | Anxiety, avoidance behavior. 10 min test. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
behavior observation | Wildness scoring. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
monitoring system | Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
body size and weight | Body weight, body length, tail length. | CC diallel w/par (62) | both | 7-15wks | 2011 |
|
|
metabolic panel | Clinical blood chemistry. 16h fast. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
complete blood count | Hematology. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 10 min test. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
light-dark box | Anxiety, avoidance behavior. 10 min test. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
behavior observation | Wildness scoring. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
monitoring system | Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
body size and weight | Body weight, tail length. | CC pre w/par (367) | both | 7-15wks | 2011 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
visual cliff | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
tail suspension test | Frequency climbing, time immobile, latency immobile. 5 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
body weight | Body weight | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
study archive
with ethanol |
Sensitivity to ethanol. Baseline and ethanol. | QTL population | both | 9-34wks | 2012 |
|
|
body weight
with high-fat diet |
Body weight and growth curve from age 1wk to 22wks (pre-wean, post-wean, adult). High-fat diet (17wks) vs. control. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
glucose tolerance
with high-fat diet |
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
lipid profile
with high-fat diet |
Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
hormone quantification
with high-fat diet |
Insulin, leptin. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | F1 8way (63) | both | 7-8wks | 2004 |
|
|
complete blood count | Hematology. | CC pre w/par (139) | m | 10-14wks | 2012 |
|
|
hormone quantification
with Staphylococcus aureus |
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. | inbred (13) | f | 8wks | 2012 |
|
|
balance beam
with ethanol |
Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. | inbred (8) | both | 8wks | 2003 |
|
|
grid test
with ethanol |
Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. | inbred (8) | both | 8wks | 2003 |
|
|
body weight
with ethanol |
Body weight | inbred (8) | both | 8wks | 2003 |
|
|
rotarod
with diazepam |
Latency to fall from 5 rpm rotarod immediately after diazepam injection. | inbred (15) | both | 6-7wks | 1998 |
|
|
drug and metabolite quantification
with diazepam |
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. | inbred (15) | both | 6-7wks | 1998 |
|
|
monitoring system
with diazepam |
Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. | inbred (15) | both | 6-7wks | 1998 |
|
|
body temperature
with diazepam |
Baseline vs. 30 min after diazepam injection (several doses). | inbred (15) | both | 6-7wks | 1998 |
|
|
rotarod
with ethanol |
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. | inbred (22) | both | 9-17wks | 2003 |
|
|
dowel balance test
with ethanol |
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. | inbred (21) | both | 9-17wks | 2003 |
|
|
vertical wire mesh
with ethanol |
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. | inbred (21) | both | 9-17wks | 2003 |
|
|
grip strength
with ethanol |
Baseline vs. 30 min after ethanol 2 g/kg i.p. | inbred (21) | both | 9-17wks | 2003 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. | inbred (21) | both | 9-17wks | 2003 |
|
|
parallel rod floor test
with ethanol |
Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. | inbred (8) | both | 7-14wks | 2005 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
inclined screen test
with haloperidol |
Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
open field test
with haloperidol |
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
behavior observation
with haloperidol |
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
body weight | Body weight | BXD w/par (55) | both | 10-16wks | 2018 |
|
|
open field test | Locomotor activity and exploratory behavior. 20 min test. | BXD w/par (55) | both | 10-16wks | 2018 |
|
|
radial maze | Spatial learning. | BXD w/par (55) | both | 10-16wks | 2018 |
|
|
behavior observation | Inter-male agression. | BXD w/par (55) | both | 10-16wks | 2018 |
|
|
open field test | Locomotor response to novelty, habituation. | CC w/par (18) | both | 10-39wks | 2023 |
|
|
bottle choice test | Palatable food consumption, preference for Boost solution. | CC w/par (18) | both | 10-39wks | 2023 |
|
|
operant conditioning chamber | Reversal learning (impulsive action) and delay discounting (impulsive choice). | CC w/par (18) | both | 10-39wks | 2023 |
|
|
open field test
with cocaine |
Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
light-dark box | Distance traveled, ambulatory time and counts, resting time, stereotypic time and counts, jumping time and counts, vertical time and counts, time in light/dark. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
hole board test | Number of entries, novel entries, and repeat entries. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
conditioned place preference test | In novel zone: exploration counts, entrance counts, time spent, activity counts, movement counts. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
operant conditioning chamber
with cocaine |
Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
in vitro assay | Circadian parameters in fibroblast cultures: period, amplitude, phase, damping rate, goodness of fit. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
body weight | Body weight | inbred (13) | both | 10wks | 2004 |
|
|
operant conditioning chamber | Sign tracking and goal tracking paradigm with Pavlovian conditioned approach. | inbred (5) | both | 12-20wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity and exploratory behavior. 20 min test. | DO population | both | 12-16wks | 2015 |
|
|
hole board test
with cocaine |
Exploratory behavior. 10 min test. | DO population | both | 12-16wks | 2015 |
|
|
monitoring system
with cocaine |
Novelty preference test (preference for novel side vs. familiar side). 10 min test. | DO population | both | 12-16wks | 2015 |
|
|
operant conditioning chamber
with cocaine |
Intravenous self-administration of cocaine via activation of levers. | DO population | both | 12-16wks | 2015 |
|
|
body weight | Body weight | BXD w/par (66) | both | 10wks | 2010 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | inbred w/CC7 (34) | m | 10wks | 2012 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | CC pre w/par (163) | m | 10wks | 2012 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. | inbred w/CC7 (30) | both | 15-16wks | 2002 |
|
|
metabolic panel | Thyroxine (serum). | inbred w/CC7 (30) | both | 15-16wks | 2002 |
|
|
hormone quantification | Osteocalcin, insulin-like growth factor 1. | inbred w/CC7 (30) | both | 15-16wks | 2002 |
|
|
DXA | Body mass, fat mass, bone mineral density. | B6.A consomic w/par (23) | both | 24-29wks | 2012 |
|
|
body weight | Pup body weight at day 3. | inbred (15) | f | 6-8wks | 2010 |
|
|
body weight | Pup body weight at day 3. | B6.A consomic w/par (22) | f | 6-8wks | 2010 |
|
|
body weight | Body weight | inbred (10) | both | 16wks | 2004 |
|
|
open field test | Locomotor activity, anxiety-related behavior, involuntary movement. 10 min test. | B6.A consomic w/par (22) | both | 6-7wks | 2011 |
|
|
hole board test | Exploratory behavior. 10 min test. | B6.A consomic w/par (22) | both | 6-7wks | 2011 |
|
|
open field test | Locomotor activity, anxiety-related behavior, involuntary repetitive movement. 10 min test. | B6.PWD consomic w/par (28) | both | 6wks | 2011 |
|
|
immunoglobulin quantification | Immunoglobulin concentrations (plasma). | B6.A consomic w/par (22) | both | 9wks | 2012 |
|
|
immunoglobulin quantification | Immunoglobulin concentrations (plasma). | B6.PWD consomic w/par (28) | both | 9wks | 2011 |
|
|
metabolic panel | Clinical blood chemistry (serum). 4h fast. | B6.PWD consomic w/par (25) | both | 11wks | 2011 |
|
|
study archive | Urinalysis. Creatinine, microalbumin, body weight. | QTL population | m | 8-10wks | 2008 |
|
|
study archive | Sterility investigation. Sperm count, testes weight. | QTL population | m | 9wks | 2012 |
|
|
complete blood count | Hematology. | inbred (8) | both | 12wks | 2007 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. | inbred (8) | both | 12wks | 2007 |
|
|
metabolic panel | Clinical blood chemistry (plasma). Unknown fast. | inbred (8) | both | 12wks | 2007 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content. | inbred (5) | both | 12, 24, 52 wks | 2008 |
|
|
glucose tolerance | 0 to 180 min after 20% glucose i.p. 16h fast. | inbred (4) | both | 12, 24, 52 wks | 2008 |
|
|
intake monitoring | Food intake. Daily. | inbred (4) | both | 12, 24 wks | 2008 |
|
|
body temperature | Hourly readings in cold room. 6h test. | inbred (4) | both | 12wks | 2008 |
|
|
immunoglobulin quantification | Immunoglobulin concentrations (serum). | inbred (6) | both | 9-12wks | 2008 |
|
|
body weight | Body weight | inbred (14) | both | 9-12wks | 2003 |
|
|
body weight | Body weight | inbred (14) | both | 25wks | 2009 |
|
|
monitoring system | Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. | inbred (14) | both | 25wks | 2009 |
|
|
intake monitoring | Food intake, water intake at 6mo. Light phase, dark phase, total. | inbred (14) | both | 25wks | 2009 |
|
|
study archive | Colitis susceptibility, severity. Colon histopathology, body and spleen weight. | QTL population | both | 6wks | 2001 |
|
|
study archive | Blood pressure (tail cuff), kidney weight, body weight. | QTL population | m | 8wks | 2009 |
|
|
body weight
with influenza A (H1N1) virus |
Body weight | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
bottle choice test
with ethanol |
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). | inbred (22) | both | 8-12wks | 2007 |
|
|
elevated zero maze | Anxiety-related behaviors. | inbred (8) | both | 8-9wks | 2001 |
|
|
electroconvulsion test
with lamotrigine |
Electroconvulsive thresholds. Lamotrigine. 2 test sites. | inbred (16) | both | 6-11wks | 2000 |
|
|
tail suspension test
with imipramine |
Immobility. Baseline (saline) vs. imipramine i.p. 6 min test. | inbred (12) | m | 5-10wks | 2003 |
|
|
light-dark box
with imipramine |
Anxiety-related behavior. Baseline (saline) vs. imipramine i.p. 10 min test. | inbred (12) | m | 5-10wks | 2003 |
|
|
open field test
with imipramine |
Locomotor activity, exploratory and anxiety-related behavior. Baseline (saline) vs. imipramine i.p. | inbred (12) | m | 5-10wks | 2003 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test some at 5 min intervals. | inbred w/CC8 (8) | both | 8-9wks | 2020 |
|
|
grip strength | Several trials. | inbred w/CC8 (8) | both | 8-10wks | 2020 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | inbred w/CC8 (8) | both | 8-10wks | 2020 |
|
|
rotarod | Latency to fall from accelerating rotarod. | inbred w/CC7 (7) | both | 9-10wks | 2020 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | inbred w/CC8 (8) | both | 9-10wks | 2020 |
|
|
metabolic panel | Glucose, glycerol. 16h fast. | inbred (5) | both | 10-11wks | 2020 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. | inbred (5) | both | 10-11wks | 2020 |
|
|
monitoring system | Locomotor activity and energy metabolism. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
intake monitoring | Food, water intake. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
NMR | Body mass, fat and lean tissue mass. | inbred w/CC8 (8) | both | 12-13, 18-19wks | 2020 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | inbred w/CC8 (6) | both | 13-14wks | 2020 |
|
|
complete blood count | Hematology. | inbred w/CC8 (8) | both | 20-21wks | 2020 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
lipid profile | Cholesterol, triglycerides. No fast, plasma. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
body size and weight | Body weight and length. | inbred w/CC8 (8) | both | 17-18wks | 2020 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | inbred w/CC8 (8) | both | 17-18wks | 2020 |
|
|
immunoglobulin quantification | Immunoglobulins (plasma). | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
autoantibody quantification | Anti-DNA autoantibodies, rheumatoid factor. | inbred w/CC8 (8) | both | 16-17, 20-21wks | 2020 |
|
|
open field test | Locomotor activity, exploratory and anxiety-related behavior. | inbred (8) | m | 10wks | 2003 |
|
|
forced swim test
with lithium |
Lithium (several doses) vs. control. 6 min test. | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with lithium |
Lithium concentration in brain tissue and blood serum after lithium (several doses). | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with nicotine |
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. | inbred (8) | m | 8-12wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
conditioned place preference test
with nicotine |
Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). | inbred (8) | m | 8-10wks | 2014 |
|
|
body weight
with West Nile virus |
Body weight | CC RIX (5) | m | 8-10wks | 2015 |
|
|
RNA expression profiling
with West Nile virus |
Viral load and expression of Ifnb1 and Ifit1 in brain, kidney and spleen. | CC RIX (5) | m | 8-10wks | 2015 |
|
|
colony observation
with SARS-CoV |
Body weight loss and mortality. | CC RIX (117) | f | 8-10wks | 2021 |
|
|
immune cell quantification | Baseline splenic T cell subsets. | CC RIX (104) | m | 8-10wks | 2021 |
|
|
complete blood count
with ENU |
Hematology. | inbred (20) | both | 9wks; 12-64wks | 2006 |
|
|
histopathology
with ENU |
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. | inbred (20) | both | 9wks; 12-64wks | 2006 |
|
|
genotype assessment
with Candida albicans |
C5 allele sufficiency or deficiency. | inbred (36) | f | 8-12wks | 2011 |
|
|
study archive | Kidney morphology, renal cystic disease severity. | QTL population | f | 2wks | 2000 |
|
|
body weight | Body weight of newborns. | inbred (8) | both | postnatal | 2011 |
|
|
body weight | Body weight of newborns. | BXH (10) | both | postnatal | 2011 |
|
|
colony observation | Maternal nurturing study. | inbred (31) | f | 14-18wks | 2012 |
|
|
body weight | Daily body weight gain of cross-fostered pups. | inbred (31) | f | 14-18wks | 2012 |
|
|
mineral quantification | concentrations of various minerals in milk | inbred (31) | f | 14-20wks | 2018 |
|
|
study archive | eQTL, urinary albumin excretion using microarray. | QTL population | m | 8-10wks | 2011 |
|
|
body weight | Body weight | DO population | both | 8-60 wks | 2020 |
|
|
body weight | Body weight | inbred (14) | m | 8-10wks | 2010 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. | HMDP (99) | m | 16wks | 2010 |
|
|
fear conditioning test | Contextual fear, cued fear. | HMDP (94) | m | 10wks | 2011 |
|
|
complete blood count | Hematology. | HMDP (83) | m | 16wks | 2013 |
|
|
study archive
with high-fat diet |
Lipids, atherosclerosis lesions, parathyroid hormone after high-fat diet. | QTL population | f | 20wks | 2004 |
|
|
body weight | Body weight and growth curve from age 3wks to 10 wks, weighed weekly. | inbred (24) | both | 8wks | 2000 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test, some at 5 min intervals. | CC (18) | both | various | 2018 |
|
|
hole board test | Exploratory behavior. | CC (18) | both | various | 2018 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | CC (18) | both | various | 2018 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | CC (18) | both | various | 2018 |
|
|
tail suspension test | Latency to immobility, duration of immobility. | CC (18) | both | various | 2018 |
|
|
rotarod | Latency to fall from accelerating rotarod. 5 trials. | CC (18) | both | various | 2018 |
|
|
grip strength | 3 trials. | CC (18) | both | various | 2018 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | CC (18) | both | various | 2018 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | CC (18) | both | various | 2018 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | CC (18) | both | various | 2018 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. No fast, plasma. | CC (18) | both | various | 2018 |
|
|
hormone quantification | Insulin (plasma). | CC (18) | both | various | 2018 |
|
|
complete blood count | Hematology. | CC (18) | both | various | 2018 |
|
|
grip strength | 3 trials. | KOMP | both | 8-18wks | 2021 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test, some at 5 min intervals. | KOMP | both | 8-18wks | 2021 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | KOMP | both | 8-18wks | 2021 |
|
|
Y-maze | Spontaneous alternation and other parameters. 8 min test. | KOMP | both | 8-18wks | 2021 |
|
|
hole board test | Exploratory behavior. | KOMP | both | 8-18wks | 2021 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | KOMP | both | 8-18wks | 2021 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | KOMP | both | 8-18wks | 2021 |
|
|
rotarod | Latency to fall from accelerating rotarod. 5 trials. | KOMP | both | 8-18wks | 2021 |
|
|
tail suspension test | Latency to immobility, duration of immobility. | KOMP | both | 8-18wks | 2021 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 8-18wks | 2021 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | KOMP | both | 8-18wks | 2021 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. | KOMP | both | 8-18wks | 2021 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | KOMP | both | 8-18wks | 2021 |
|
|
monitoring system | Sleep parameters, light and dark periods. | KOMP | both | 8-18wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | KOMP | both | 8-18wks | 2021 |
|
|
complete blood count | Hematology parameters. | KOMP | both | 8-18wks | 2021 |
|
|
hormone quantification | Insulin (plasma). | KOMP | both | 8-18wks | 2021 |
|
|
grip strength | 3 trials. | KOMP | both | 66-81wks | 2021 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test, some at 5 min intervals. | KOMP | both | 66-81wks | 2021 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | KOMP | both | 66-81wks | 2021 |
|
|
Y-maze | Spontaneous alternation and other parameters. 8 min test. | KOMP | both | 66-81wks | 2021 |
|
|
hole board test | Exploratory behavior. | KOMP | both | 66-81wks | 2021 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | KOMP | both | 66-81wks | 2021 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | KOMP | both | 66-81wks | 2021 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 66-81wks | 2021 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | KOMP | both | 66-81wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | KOMP | both | 66-81wks | 2021 |
|
|
complete blood count | Hematology parameters. | KOMP | both | 66-81wks | 2021 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
complete blood count | Hematology. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
body weight | Body weight and growth curve from age 3wks to 16wks, weighed weekly. | inbred (10) | both | 3-16wks | 2014 |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | inbred (6) | m | 10wks | 2010 |
|
|
grip strength | Peak tension. | inbred (6) | m | 10wks | 2010 |
|
|
rotarod | Latency to fall from accelerating rotarod. | inbred (6) | m | 10wks | 2010 |
|
|
body weight | Body weight | inbred (7) | both | 8-14wks | 2003 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content (whole body, femur, spine). | inbred (7) | both | 8-14wks | 2003 |
|
|
operant conditioning chamber | Reversal learning test. Impulsivity, acquisition, reversal, conditioning. Performance and latency. | BXD w/par (53) | m | 17wks | 2011 |
|
|
operant conditioning chamber
with cocaine |
Intravenous self-administration of cocaine via activation of levers, and locomotor activity. | BXD (4) | both | 8-17wks | 2013 |
|
|
complete blood count | Hematology. | inbred (16) | both | 12-16wks | 2002 |
|
|
study archive | Characterization of high-muscle-mass mice. | QTL population | both | 3-10wks | 2011 |
|
|
balance beam | Latency to reach target. | inbred (6) | m | 20-34wks | 2009 |
|
|
grid test | Inverted grid performance. | inbred (6) | m | 20-34wks | 2009 |
|
|
home cage monitoring | Locomotor activity. | inbred (6) | m | 20-34wks | 2009 |
|
|
study archive | Glucose, insulin, body and fat pad weights. | QTL population | m | 20-26wks | 2001 |
|
|
histopathology
with cadmium |
Cadmium-induced toxicity to liver, testis, trigeminal ganglia. | inbred (8) | m | 8wks | 2001 |
|
|
monitoring system | Activity in a novel environment. Distance traveled, number of rears. 30 min test. | inbred (14) | both | 8wks | 2006 |
|
|
two chamber assay | Novel environment preference. Activity in familiar and novel compartments. 20 min test. | inbred (14) | both | 8wks | 2006 |
|
|
hole board test | Head dipping and other activity measures, hole board with and without objects in two of the holes. 10 min test. | inbred (14) | both | 8wks | 2006 |
|
|
Y-maze | Spontaneous alternation. | inbred (14) | both | 8wks | 2006 |
|
|
avoidance test | Active and passive. | wild-derived Mishima (11) | f | 8-13wks | 2000 |
|
|
home cage monitoring | Locomotor activity. | wild-derived Mishima (11) | f | 8-13wks | 2000 |
|
|
light-dark box | Anxiety-related behavior. | wild-derived Mishima (11) | f | 8-13wks | 2000 |
|
|
open field test | Exploratory, anxiety-related behavior. 10 min test. | wild-derived Mishima (12) | both | 10wks | 2006 |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
study archive
with cocaine |
Open field test. Locomotor, anxiety-related, circadian behavior. Baseline and after cocaine i.p. | QTL population | both | 10-14wks | 2014 |
|
|
open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 |
|
|
body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
complete blood count | Hematology. | B6.A consomic w/par (23) | both | 7-11wks | 2005 |
|
|
metabolic panel | Glucose, bilirubin, aspartate transaminase (plasma). 4h fast. | B6.A consomic w/par (23) | both | 7-11wks | 2005 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. | B6.A consomic w/par (23) | both | 7-11wks | 2005 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | B6.A consomic w/par (23) | both | 8wks | 2005 |
|
|
rotarod | Latency to fall from fixed and accelerating rotorods, multiple trials. | B6.A consomic w/par (23) | both | 8-9wks | 2005 |
|
|
hole board test | Exploratory, locomotor, and anxiety-related behavior. | B6.A consomic w/par (23) | both | 8-9wks | 2005 |
|
|
grip strength | 3 trials. | B6.A consomic w/par (23) | both | 8-9wks | 2005 |
|
|
study archive | Type 1 diabetes development study. | QTL population | f | 14-40wks | 2009 |
|
|
body weight | Body weight | CC pre (31) | both | 8-14wks | 2015 |
|
|
study archive
with western diet |
Lipids, atherosclerosis lesion histopathology. High-fat, western-style diet. | QTL population | f | 12wks | 2008 |
|
|
body weight | Body weight | inbred (41) | both | 8-9wks | 2010 |
|
|
running wheel monitoring | Distance, duration, speed. | inbred (41) | both | 8-9wks | 2010 |
|
|
body weight
with exercise |
Exercise (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
microscopy
with exercise |
Muscle fibers. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
muscle weights
with exercise |
Various muscles. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
organ weights
with exercise |
Heart weight. Cardiac ventricle weight. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
bone dimensions
with exercise |
Femur length. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
swim endurance test
with exercise |
Exercise vs. control, weekly for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
protein activity assessment
with exercise |
Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
home cage monitoring | Locomotor activity, avoidance, sheltering, habituation, preference index, aversion index, over several days. | inbred (8) | m | 8-19wks | 2012 |
|
|
home cage monitoring | Locomotor activity, sheltering, habituation. 3 day home-cage assessment. | inbred w/CC7 (11) | m | 8-12wks | 2016 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), bile, liver weight, gallbladder and gallstone histopathology. | QTL population | m | 16-18wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids, gallbladder and gallstone histopathology after high-fat diet. | QTL population | m | 14-20wks | 2004 |
|
|
body weight | Body weight | CC (16) | both | 10wks | 2015 |
|
|
rotarod | Speed where mouse falls off accelerating rotarod, 45 degree angle, 3-5 trials. | CC (16) | both | 10wks | 2015 |
|
|
body weight | Body weight | inbred (34) | both | 8wks | 2012 |
|
|
treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 |
|
|
body weight
with exercise |
Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
MRI
with exercise |
Body composition (percent fat). Baseline vs. after exercise (access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
intake monitoring
with exercise |
Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
monitoring system
with exercise |
Respiratory exchange ratio. Baseline (before access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
running wheel monitoring
with exercise |
Distance, speed at days 1, 6, and 12. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
study archive | Type 1 diabetes resistance. | QTL population | f | 8-40wks | 2003 |
|
|
body weight
with atenolol, isoproterenol |
Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
organ weights
with atenolol, isoproterenol |
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
tail cuff
with atenolol, isoproterenol |
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
ECG
with atenolol, isoproterenol |
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
MRI | Body composition (fat and lean mass and percent). | CC (50) | f | 17-72wks | 2017 |
|
|
treadmill endurance test | Maximal distance is recorded when mouse fails to run. | CC (50) | f | 17-72wks | 2017 |
|
|
running wheel monitoring | Running wheel activity each day for 28 days. | CC (43) | f | 5-22wks | 2017 |
|
|
body weight | Body weight before, during, and after several weeks of exercise. | CC (43) | f | 20-88wks | 2017 |
|
|
MRI | Body composition (fat and lean mass) before, during, and after several weeks of exercise. | CC (43) | f | 20-88wks | 2017 |
|
|
intake monitoring | Food intake, before, during, and after several weeks of exercise. | CC (43) | f | 20-88wks | 2017 |
|
|
body weight
with exercise |
Body weight before and after 2 weeks of exercise wheel availability. | CC (13) | f | 32-40wks | 2018 |
|
|
MRI
with exercise |
Body composition (fat and lean mass) before and after 2 weeks of exercise wheel availability. | CC (13) | f | 32-40wks | 2018 |
|
|
running wheel monitoring
with exercise |
Running wheel activity on days 11 and 12. | CC (13) | f | 32-40wks | 2018 |
|
|
intake monitoring
with exercise |
Food intake during 2 weeks of exercise wheel availability. | CC (13) | f | 32-40wks | 2018 |
|
|
body weight
with exercise |
Body weight before and after 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
MRI
with exercise |
Body composition (fat and lean mass) before and after 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
monitoring system
with exercise |
Locomotor activity, respiratory activity, body heat production, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
intake monitoring
with exercise |
Food and water intake, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
behavior observation
with ethanol |
Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). | inbred (9) | both | 8-11wks | 2004 |
|
|
open field test
with ethanol |
Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. | inbred (9) | both | 8-11wks | 2004 |
|
|
body weight
with ethanol |
Body weight | inbred (15) | m | 8-11wks | 2005 |
|
|
behavior observation
with ethanol |
Ethanol withdrawal severity and handling-induced convulsions. | inbred (15) | m | 8-11wks | 2005 |
|
|
go/no-go task | Pre-cue, go cue. no-go cue. Discrimination index. | inbred (15) | m | 5-7wks | 2010 |
|
|
monitoring system | Locomotor activity. | inbred (15) | m | 5-7wks | 2010 |
|
|
monitoring system | Locomotor activity. Light and dark phases. | inbred (12) | m | 6-10wks | 2000 |
|
|
monitoring system | Social interaction and discrimination; activity, digging, grooming. | CC (52) | m | 7-20wks | 2018 |
|
|
body weight | Body weight | CC (52) | m | 7-20wks | 2018 |
|
|
protein activity assessment | Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus | inbred (20) | m | 8-12wks | 2021 |
|
|
body weight
with high-fat diet and olanzapine |
Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). | inbred w/CC8 (9) | f | 8-18wks | 2014 |
|
|
three chamber assay | Sociability and preference for social novelty. Autism-relevant behaviors. | inbred (17) | m | 6-7wks | 2008 |
|
|
study archive | Kidney morphology. | QTL population | both | 1-2wks | 2005 |
|
|
body weight
with high-fat diet |
Baseline vs. high-fat diet for 12wks. | B6.A consomic w/par (24) | m | 5, 17 wks | 2008 |
|
|
body size and weight
with high-fat high-sucrose diet |
Body weight, size, and body mass index after 16wks on high-fat high-sucrose diet. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
metabolic panel
with high-fat high-sucrose diet |
Glucose, insulin, insulin resistance after 16wks of high-fat high-sucrose diet. 16h fast. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. | B6.A consomic w/par (24) | m | 5, 21 wks | 2015 |
|
|
body weight
with high-fat high-sucrose diet |
After 16 wks on high-fat high-sucrose diet. | inbred (2) | m | 21 wks | 2016 |
|
|
body size and weight
with high-fat high-sucrose diet |
Body weight and body mass index after 16 wks of high-fat high-sucrose diet. | inbred (2) | m | 21 wks | 2016 |
|
|
hormone quantification
with high-fat high-sucrose diet |
Insulin and insulin resistance after 16 wks of high-fat high-sucrose diet. Overnight fast. | inbred (2) | m | 21 wks | 2016 |
|
|
lipid profile
with high-fat high-sucrose diet |
Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. | inbred (2) | m | 21 wks | 2016 |
|
|
body weight
with high-fat high-sucrose diet |
High-fat high-sucrose diet for 14-15 wks | B6.A consomic w/par (3) | m | 4-19 wks | 2016 |
|
|
body size and weight
with high-fat high-sucrose diet |
Body length and body mass index after high-fat high-sucrose diet for 14-15 wks | B6.A consomic w/par (3) | m | 4-19 wks | 2016 |
|
|
body weight
with high-fat diet |
High-fat diet for 8wks. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
DXA
with high-fat diet |
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
metabolic panel
with high-fat diet |
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
hormone quantification
with high-fat diet |
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
body weight
with restricted diet |
Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
NMR
with restricted diet |
Body mass, fat mass, lean mass. Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
colony observation
with restricted diet |
Life span comparison. Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
body weight | Measured every 2 mo, starting at age 2 mo to 16 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
Y-maze | Spontaneous alternation and other parameters measured every 2 mo, from age 2 to 16 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
balance beam | Time to cross narrow beam, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
inclined screen test | Time to right body, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
grip strength | Grip strength across 3 trials, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
behavior observation | Sensorimotor composite score, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
elevated plus maze | Distance traveled and arm entries, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
fear conditioning test | Time spent freezing, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
immunoglobulin quantification | IgM, IgG1, IgG2a + IgG2c, IgG2b, IgG3, total IgG | CC RIX (46) | f | 8-12 wks of age | 2020 |
|
|
body weight | Body weight | inbred (8) | m | 10-66wks | 2015 |
|
|
metabolic panel | Male reproductive sperm lactate production. | inbred (8) | m | 10-66wks | 2015 |
|
|
body weight
with high-fat diet |
Baseline vs. high-fat diet for 8wks. | inbred (44) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
metabolic panel
with high-fat diet |
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | inbred (44) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 |
|
|
body weight
with high-fat diet |
Baseline vs. high-fat diet for 8wks. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
metabolic panel
with high-fat diet |
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | obesity mutants (8) | both | 15-19wks | 2000 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. | inbred w/CC7 (43) | both | 10wks | 2002 |
|
|
fear conditioning test | Innate anxiety-like behavior and contextual fear conditioning. | B6.A consomic w/par (19) | both | 10wks | 2007 |
|
|
open field test
with methamphetamine |
Locomotor activity and habituation. Baseline (saline) vs. methamphetamine 2 mg/kg i.p. 30 min test. | B6.A consomic w/par (21) | both | 10wks | 2008 |
|
|
body weight | Body weight | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
open field test | Locomotor and exploratory behavior. 30 min test. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
fear conditioning test | Contextual fear, cued fear. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
forced swim test | Immobility time. 6 min test. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
metabolic panel | Glucose (blood). Before and after 16h fast. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
body weight
with methamphetamine |
Body weight | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
light-dark box
with methamphetamine |
Anxiety-related. 5 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
open field test
with methamphetamine |
Locomotor and exploratory activity, anxiety-related behavior, methamphetamine sensitivity. 30 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
forced swim test
with methamphetamine |
Immobility time. 6 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
acoustic startle test
with methamphetamine |
Acoustic startle response. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
body weight | Body weight | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
open field test | Locomotor and exploratory behavior. 30 min test. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
fear conditioning test | Contextual fear, cued fear. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
forced swim test | Immobility time. 6 min test. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
metabolic panel | Glucose (blood). Before and after 16h fast. | F1 Tcf7l2 (30) | both | 7-14wks | 2017 |
|
|
body weight
with methamphetamine |
Body weight | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
light-dark box
with methamphetamine |
Anxiety-related. 5 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
open field test
with methamphetamine |
Locomotor and exploratory activity, anxiety-related behavior, methamphetamine sensitivity. 30 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
forced swim test
with methamphetamine |
Immobility time. 6 min test. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
acoustic startle test
with methamphetamine |
Acoustic startle response. | F1 Cacna1c (30) | both | 7-14wks | 2017 |
|
|
study archive | Body weight of Gough Island mice. | QTL population | both | 1-16wks | 2015 |
|
|
complete blood count | Hematology. | inbred w/CC7 (43) | both | 10wks | 2001 |
|
|
complete blood count | Hematology. | AXB BXA (28) | both | 11wks | 2004 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 |
|
|
study archive | Complete blood count measures on fetuses, newborns. | QTL population | both | fetus, newborn | 2004 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | B6.A consomic (22) | m | 7-9wks | 2009 |
|
|
study archive
with high-fat diet |
Cholesterol (plasma) after high-fat diet (several timepoints). | QTL population | f | 6-26wks | 2002 |
|
|
body weight | Body weight | inbred (32) | m | 7-9wks | 2007 |
|
|
open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 |
|
|
tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 |
|
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
|
body size and weight | Body weight, body length, body mass index. | inbred (28) | m | 8, 12 wks | 2009 |
|
|
body size and weight | Body weight, body length, body mass index. | B6.129 and 129.B6 consomic w/par (9) | both | 26wks | 2015 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. High-fat diet vs. control. Two age cohorts. | B6.129 and 129.B6 consomic w/par (9) | both | 26wks | 2015 |
|
|
study archive | Body weight (several ages), fat mass, body mass index, fat pad weights. | QTL population | m | 4-24wks | 2000 |
|
|
study archive | Type 1 diabetes onset. | QTL population | f | 12-40wks | 2005 |
|
|
running wheel monitoring
with exercise |
Locomotor activity. Exercise wheel group vs. control group. Distance per day. | inbred (12) | both | 8-15wks | 2010 |
|
|
body weight
with exercise |
Exercise wheel group vs. control group. | inbred (12) | both | 8-15wks | 2010 |
|
|
microscopy
with exercise |
Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. | inbred (12) | both | 8-15wks | 2010 |
|
|
proteomic profiling | Hair proteomics analysis. Spectral counts for 46 specific proteins. | inbred (11) | both | 10-19wks | 2012 |
|
|
study archive
with macronutrient diet option |
Caloric intake, glucose, body and fat pad weights. Macronutrient diet option. | QTL population | m | 8-13wks | 2002 |
|
|
open field test | Locomotor activity. 3 day trials. 45 min sessions. | inbred (15) | m | 7-9wks | 2003 |
|
|
neurotransmitter quantification | Neurotransmitters. Molecular measures. | inbred (15) | m | 7-9wks | 2003 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
complete blood count | Hematology. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
body size and weight | Body weight, body length, tail length. | inbred RBRC (56) | both | 8, 12 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
complete blood count | Hematology. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
lipid profile | Cholesterol, HDL, triglycerides. 4h fast, plasma. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
body size and weight | Body weight, body length, tail length. | wild-derived RBRC (33) | both | 8, 12 wks | 2008 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. | inbred (17) | m | 7wks | 2010 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. | inbred (17) | m | 7wks | 2010 |
|
|
metabolic panel
with high-fat diet and ethanol |
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
alcohol quantification
with high-fat diet and ethanol |
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with high-fat diet and ethanol |
Liver weight after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
histopathology
with high-fat diet and ethanol |
Liver histopathology, injury after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
metabolite quantification
with high-fat diet and ethanol |
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
lipid profile
with high-fat diet and ethanol |
Hepatic triglycerides after 4wk regimen of ethanol and high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
RNA expression profiling
with high-fat diet and ethanol |
Liver gene expression after 4wk regimen of ethanol and high-fat diet. 24h fast. mRNA abundance relative to the control (high-fat only) group. | inbred (14) | m | 8-14wks | 2011 |
|
|
organ weights
with trichloroethylene |
Liver, kidney weights. Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
metabolic panel
with trichloroethylene |
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. | inbred (7) | m | 6-7wks | 2014 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. | inbred (7) | m | 6-7wks | 2014 |
|
|
RNA expression profiling
with trichloroethylene |
Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
histopathology
with trichloroethylene |
Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. | inbred (7) | m | 6-7wks | 2014 |
|
|
health assessment | Post-injury wound healing. Ear cartilage and articular cartilage. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
histopathology | Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. | LGXSM w/par (15) | both | 6-7wks | 2012 |
|
|
Morris water maze | Spatial learning and memory. Multiple trials. | inbred (8) | m | 9-11wks | 2010 |
|
|
light-dark box | Anxiety-related behavior. | inbred (8) | m | 9-11wks | 2010 |
|
|
open field test | Locomotor activity and exploratory behavior. 5 min test. | inbred (8) | m | 9-11wks | 2010 |
|
|
elevated plus maze | Anxiety-related and exploratory behavior. 5 min test. | inbred (8) | m | 9-11wks | 2010 |
|
|
puzzle box | Learning and memory. | inbred (8) | m | 9-11wks | 2010 |
|
|
tail suspension test | Duration of immobility. Two trials. | inbred (8) | m | 9-11wks | 2010 |
|
|
health assessment
with pilocarpine |
Study of pilocarpine effect on epilepticus seizures. | inbred (11) | m | 8-10wks | 2012 |
|
|
body weight
with various diets |
Body weight at weaning and time of test. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
open field test
with various diets |
Locomotor activity, anxiety-related behavior. 10 min test. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
light-dark box
with various diets |
Anxiety-related behavior. 10 min test. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
body temperature
with various diets |
Temperature before and after stress. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
forced swim test
with various diets |
Immobility time. 6 min test. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
hormone quantification
with various diets |
Serum corticosterone at baseline and 10 mins after stress. Comparison of 4 diets. | CC RIX (18) | f | 8-9 wks | 2018 |
|
|
body weight | Body weight | inbred (11) | both | 8-10wks | 2005 |
|
|
glucose tolerance | 0 to 120 min after 10% glucose i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
insulin tolerance | 0 to 120 min after insulin i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
lipid profile | Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. | inbred (11) | both | 8-10wks | 2005 |
|
|
metabolic panel | Glucose, beta-hydroxybutyrate (plasma). No fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
DXA | Fat mass. | inbred (11) | both | 8-10wks | 2005 |
|
|
hormone quantification | Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
body weight
with high-fat diet |
At 8, 20 and 29 wks of age. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
biomarker quantification
with high-fat diet |
Bile acid levels in plasma, feces, and liver. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
body weight
with influenza A (H1N1) virus |
Influenza A (H1N1) virus vs. baseline. Several timepoints. | inbred (9) | both | 10-12wks | 2009 |
|
|
body weight
with influenza A (H1N1) virus |
Influenza A (H1N1) virus vs. baseline. Several timepoints.. | BXD w/par (56) | f | 9-18wks | 2012 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. | inbred w/CC8 (8) | both | 7-13wks | 2013 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
body weight | Body weight | inbred (7) | both | 9-18wks | 2000 |
|
|
bronchoalveolar lavage assessment
with ovalbumin |
Lung inflammatory changes. Ovalbumin vs. control. | inbred (8) | m | 6-8wks | 2001 |
|
|
body weight | Body weight | inbred (16) | both | 7-9wks | 2001 |
|
|
monitoring system | Locomotor activity and energy metabolism. 24h test. | inbred (16) | both | 7-9wks | 2001 |
|
|
intake monitoring | Food, caloric, and water intake. Daily. | inbred (16) | both | 7-9wks | 2001 |
|
|
grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
study archive | Urinalysis. Creatinine, microalbumin, body weight. | QTL population | m | 10wks | 2007 |
|
|
study archive | Circadian activity. | QTL population | both | 2001 | |
|
|
observational fear learning test | Percent time freezing to conditioning and contextual exposure. | inbred (11) | m | 12-14wks | 2016 |
|
|
fear conditioning test | Pavlovian fear conditioning. | inbred (11) | m | 12-14wks | 2016 |
|
|
open field test | Locomotor activity and exploratory behavior. 5 min test. | inbred (11) | m | 12-14wks | 2016 |
|
|
elevated plus maze | Exploratory and anxiety-related behaviors. 5 min test. | inbred (11) | m | 12-14wks | 2016 |
|
|
three chamber assay | Sociability testing. Tolerance of a novel mouse, a novel object, and second novel mouse vs. first. 10 min test. | inbred (11) | m | 12-14wks | 2016 |
|
|
body weight
with high-fat diet |
High-fat diet for 4wks vs. control. | inbred (10) | both | 10-13wks | 2008 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. | inbred (10) | both | 10-13wks | 2008 |
|
|
metabolic panel
with high-fat diet |
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. | inbred (10) | both | 10-13wks | 2008 |
|
|
body weight | Body weight | CC (12) | m | 15-33wks | 2020 |
|
|
body weight | Body weight | CC RIX (28) | m | 7-44wks | 2020 |
|
|
body weight | Body weight | DO population | m | 12-15wks | 2020 |
|
|
study archive | Open field test, forced swim test, defensive burying task. | QTL population | both | 11-17wks | 2004 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | BXD w/par (45) | m | 8wks | 2011 |
|
|
choice serial reaction time task | Choice serial reaction time task. Impulsivity, attention, cognitive flexibility behavior. | BXD w/par (45) | m | 8wks | 2011 |
|
|
home cage monitoring | Exploratory behavior. 4 min and 10 min tests. | inbred (12) | m | 6wks | 2009 |
|
|
open field test | Locomotor activity and exploratory behavior. 10 min test. | inbred (12) | m | 6wks | 2009 |
|
|
light-dark box | Anxiety, avoidance behavior. 5 min test. | inbred (12) | m | 6wks | 2009 |
|
|
elevated plus maze | Exploratory and anxiety-related behaviors. 5 min test. | inbred (12) | m | 6wks | 2009 |
|
|
choice serial reaction time task | Choice serial reaction time task. Impulsivity, attention, cognitive flexibility behavior. 25 min test. | inbred (12) | m | 6wks | 2009 |
|
|
study archive
with high-fat diet |
Body size, weight, fat pad weights after high-fat diet. | QTL population | both | 24wks | 2006 |
|
|
study archive | Lipids. Cholesterol, triglycerides, body weight. | QTL population | both | 8-10wks | 2006 |
|
|
study archive
with high-fat diet |
Lipids (plasma). Cholesterol, triglycerides, aortic lesions, body mass index. | QTL population | f | 14wks | 2009 |
|
|
study archive | Blood pressure (tail cuff), heart weight, body weight. | QTL population | m | 10wks | 2002 |
|
|
body weight
with selenium |
Body weight curve 3 to 12 wks, control group. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
RNA expression profiling
with selenium |
Selenium regulation of selenoprotein enzyme activity and transcripts. | inbred w/CC8 (8) | m | 3-14wks | 2018 |
|
|
complete blood count | Hematology. | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
metabolic panel | Glucose, bilirubin, blood urea nitrogen, aspartate transaminase (plasma). 4h fast. | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | B6.PWD consomic w/par (28) | both | 9wks | 2006 |
|
|
body size and weight | Body weight, body length, body mass index. | B6.PWD consomic w/par (28) | both | 16wks | 2006 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content. | B6.PWD consomic w/par (28) | both | 16wks | 2006 |
|
|
assisted reproduction | Performance following assisted reproductive technologies. | inbred (10) | f | various | 2006 |
|
|
body weight
with cocaine |
Body weight | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with ovariectomy |
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
forced swim test
with ovariectomy |
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine i.p. (several doses). 1.3h and 2.3 h duration. | inbred (15) | both | 8-10wks | 2011 |
|
|
open field test
with R-6-Br-APB, quinelorane |
Locomotor activity. Baseline (saline) vs. dopamine agonists i.p. (several doses). 3h session. | inbred (15) | both | 8-10wks | 2011 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolic panel
with acetaminophen |
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. | inbred (5) | m | 6-8wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Glutathione. | inbred (5) | m | 6-8wks | 2005 |
|
|
drug and metabolite quantification
with acetaminophen |
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). | inbred (5) | m | 6-8wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. | inbred (5) | m | 6-8wks | 2005 |
|
|
biomarker quantification | Fibronectin. | inbred (25) | both | 9wks | 2007 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred (28) | m | 9wks | 2001 |
|
|
body weight | Body weight | inbred (28) | m | 4-12wks | 2001 |
|
|
intake monitoring | Food intake, water intake. Daily. | inbred (28) | m | 4-12wks | 2001 |
|
|
body weight | Body weight | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
metabolic panel | Ionized and total blood calcium, blood pH. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
elevated plus maze | Exploratory and anxiety-related behaviors. 5 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
open field test | Locomotor activity under dim lights vs. bright lights. 5 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
monitoring system | Novelty-induced fear test. Eating inhibition due to novelty of environment. 10 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
hormone quantification | Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). | inbred (16) | m | 6-8wks | 1993 |
|
|
study archive | Brain weight, body weight. | QTL population | both | 2005 | |
|
|
body weight | Body weight | ILSXISS (43) | both | 8-23wks | 2015 |
|
|
intake monitoring | Ethanol consumed during 2h availability during dark phase. 4 days/trials with variations. | ILSXISS (43) | both | 8-23wks | 2015 |
|
|
body weight | Body weight | inbred (21) | both | 6-8wks | 2009 |
|
|
mineral quantification | Liver mineral levels. Iron, copper, zinc. Iron homeostasis. | inbred (18) | both | 8wks | 2010 |
|
|
transferrin quantification | Diferric transferrin (plasma). | inbred (18) | both | 8wks | 2010 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 5 min test. | inbred (21) | both | 9, 12 wks | 2003 |
|
|
elevated plus maze | Locomotor, exploratory, and anxiety-related behavior. | inbred (21) | both | 9, 12 wks | 2003 |
|
|
behavior observation | Wildness scoring during various phenotyping tests. | inbred (21) | both | 10-12wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma). Cholesterol, inducibility, triglycerides, atherosclerosis lesions. | QTL population | f | 10-23wks | 2003 |
|
|
body weight | Body weight | inbred w/CC7 (40) | both | 5-6wks | 2002 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | inbred w/CC7 (40) | both | 5-6wks | 2002 |
|
|
elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 |
|
|
tail suspension test
with fluoxetine |
Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
open field test
with fluoxetine |
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
|
immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib |
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 |
|
|
study archive
with high-fat diet |
Liver weight, gallbladder and gallstone histopathology. | QTL population | both | 18-20wks | 2002 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 6-16wks | 2003 |
|
|
study archive
with high-fat diet |
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. | QTL population | both | 2005 | |
|
|
body weight | Body weight | CC RIX (73) | both | 7-13wks | 2020 |
|
|
inclined screen test | Latency to move all four paws. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
open field test | Locomotor activity, anxiety, stereotypy. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
behavior observation | Vacuous chewing, tongue protrusion, jaw tremor. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
drug and metabolite quantification | Plasma haloperidol concentration. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
body weight
with arsenic |
Baseline, then after iAs exposure for 26 wks | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
MRI
with arsenic |
Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
urinalysis
with arsenic |
Urine volume at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolic panel
with arsenic |
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification
with arsenic |
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
gait analysis | Aging study, 6mo, 12mo, 18mo. | inbred (31) | both | 26, 52, 78 wks | 2010 |
|
|
study archive | Circadian behavior. | QTL population | m | 9-34wks | 2011 |
|
|
study archive | Body weight (several timepoints) and liver weight. | QTL population | both | 2-12wks | 2007 |
|
|
body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
study archive | Plasma levels of P-selectin and soluble vascular cell adhesion molecule-1. | QTL population | f | 18wks | 2008 |
|
|
glycosylation profile | IgG glycan peaks, relative abundance | CC (111) | both | 4-140wks | 2018 |
|
|
glycosylation profile | IgG subclasses, relative abundance | CC (95) | both | 20-117wks | 2018 |
|
|
study archive
with western diet |
Atherosclerosis and glucose homeostasis. Lesions, lipids, glucose, insulin. High-fat, western-style diet. | QTL population | f | <6-18wks | 2012 |
|
|
body weight | inbred (30) | both | 7-15 wks | 2020 | |
|
|
intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |